Troglitazone-induced liver failure: a case study (Q44394235)

2 December 2017

Troglitazone-induced liver failure: a case study (English)

1 reference

2 December 2017

1 reference

David J Graham

1

1 reference

2 December 2017

Lanh Green

series ordinal

2

1 reference

2 December 2017

John R Senior

series ordinal

3

1 reference

2 December 2017

Parivash Nourjah

series ordinal

4

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

American Journal of Medicine

2 December 2017

1 reference

2 December 2017

114

1 reference

2 December 2017

299-306

1 reference

2 December 2017

4

1 reference

A novel antidiabetic drug, troglitazone--reason for hope and concern.

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Fatal hepatotoxicity associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

An autopsy case of troglitazone-induced fulminant hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Severe hepatotoxicity associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Rapid-onset subfulminant liver failure associated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Liver enzyme monitoring in patients treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Principles of signal detection in pharmacovigilance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Adverse-drug-reaction monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Under-reporting of adverse drug reactions in general practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Classification, etiology, and considerations of outcome in acute liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Fulminant and subfulminant liver failure: definitions and causes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Using numerical results from systematic reviews in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

A Japanese case of liver dysfunction after 19 months of troglitazone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Hepatic injury due to troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Severe but reversible hepatitis induced by troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Toxic effect of troglitazone on cultured rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

Cholestatic hepatitis associated with flucloxacillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901529-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(02)01529-2

1 reference

2 December 2017

1 reference